News headlines about Lannett (NYSE:LCI) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lannett earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.86231363008 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern’s analysis:
- Lannett Company, Inc. (LCI) Reaches $15.60 After 6.00% Up Move; Vina Concha Y Toro (VCO) SI Decreased By 24.29% (mtastar.com)
- Lannett Company, Inc. (LCI) expected to touch -11.04% EPS growth for coming year (wallstreetinvestorplace.com)
- Analysts assigned mean rating score of 2.50 for Lannett Company, Inc. (LCI) (wallstreetmorning.com)
- Lannett Company, Inc. (LCI) Stock Recent Trading Summary: (thestocksnews.com)
- Zacks: Brokerages Anticipate Lannett Company, Inc. (LCI) Will Post Earnings of $0.76 Per Share (americanbankingnews.com)
A number of brokerages recently issued reports on LCI. BMO Capital Markets reduced their target price on Lannett from $22.00 to $21.00 and set a “market perform” rating for the company in a research note on Thursday, February 8th. Oppenheimer restated a “hold” rating on shares of Lannett in a research note on Wednesday, February 7th. Zacks Investment Research lowered Lannett from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Roth Capital set a $25.00 target price on Lannett and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Finally, ValuEngine lowered Lannett from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $20.83.
Lannett (NYSE:LCI) last announced its quarterly earnings results on Wednesday, February 7th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.20. The company had revenue of $184.31 million for the quarter, compared to the consensus estimate of $190.92 million. Lannett had a return on equity of 18.85% and a net margin of 7.44%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the firm earned $0.92 EPS. analysts forecast that Lannett will post 3.13 EPS for the current year.
In other Lannett news, major shareholder David Farber sold 10,000 shares of the stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $25.01, for a total transaction of $250,100.00. Following the sale, the insider now directly owns 4,171,269 shares of the company’s stock, valued at approximately $104,323,437.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 14.72% of the stock is currently owned by company insiders.
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.